1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

HitGen’s DEL Platform Powers BioAge’s Obesity Drug Into the Clinic

16 Sep 2025
Admin
News Article

HitGen’s DEL Platform Powers BioAge’s Obesity Drug Into the Clinic

Chengdu, China – HitGen Inc. (SSE: 688222.SH) announced that partner BioAge Labs, Inc. (NASDAQ: BIOA) has begun a Phase 1 clinical trial of BGE-102, a first-in-class NLRP3 inhibitor discovered using HitGen’s DNA-encoded library (DEL) technology. The milestone triggers an undisclosed payment to HitGen under its collaboration with BioAge.

BGE-102: A Novel NLRP3 Inhibitor

Mechanism: Orally available, brain-penetrant small molecule inhibitor of NLRP3 inflammasome.
Indication: Being developed for obesity, with potential applications in neurodegenerative, cardiovascular, and metabolic diseases linked to chronic inflammation.
Preclinical data: Showed significant weight loss as monotherapy and in combination with GLP-1 receptor agonists.
Clinical status: A SAD/MAD Phase 1 trial is ongoing, with initial single-ascending dose data expected by end of 2025.

Collaboration Milestones

April 2021: HitGen and BioAge identified promising NLRP3 hits from DEL screening.
Feb 2024: Joint publication in Bioorganic & Medicinal Chemistry Letters detailing discovery of indazole NLRP3 inhibitors.
2024–2025: Co-filed patents on structurally novel compounds.
Sept 2025: BioAge advances BGE-102 into the clinic, triggering a milestone payment to HitGen.

Leadership Commentary

Dr. Jin Li, Chairman & CEO, HitGen:

“The advancement of BGE-102 validates the power of our DEL platform to discover novel small molecules against challenging targets and reinforces the value of our partnership model.”

Dr. Kristen Fortney, CEO & Co-founder, BioAge:

“HitGen’s DEL platform enabled us to identify NLRP3 inhibitors with a novel binding site, strong potency, and brain penetration. Together we’re advancing transformative therapies for metabolic diseases.”

Company Profiles

HitGen Inc.

Global leader in DNA-encoded library screening, with 1.2 trillion molecules in its libraries.
Platforms: DEL, fragment-based drug discovery, structure-based design, targeted protein degradation, oligonucleotide therapeutics.
Expanding DEL+AI+automated DMTA optimization capabilities.
Partnerships with hundreds of biopharma companies worldwide.

BioAge Labs, Inc.

Clinical-stage biotech targeting the biology of human aging.
Pipeline focus: obesity and metabolic diseases.
Lead asset BGE-102: NLRP3 inhibitor in Phase 1.
Additional programs: long-acting injectable/oral APJ agonists and preclinical metabolic aging pathways.

Industry Context

NLRP3 inflammasome is emerging as a hot drug target for metabolic, neurodegenerative, and cardiovascular diseases.
Competitors include Inflazome (acquired by Roche) and Novartis, both developing inflammasome inhibitors.
If successful, BGE-102 could provide a novel anti-inflammatory approach to obesity, potentially complementing or competing with GLP-1 therapies like semaglutide.